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ABSTRACT
There is an increasing interest in using single nu-
cleotide polymorphism (SNP) genotyping arrays for
profiling chromosomal rearrangements in tumors,
as they allow simultaneous detection of copy
number and loss of heterozygosity with high reso-
lution. Critical issues such as signal baseline shift
due to aneuploidy, normal cell contamination, and
the presence of GC content bias have been
reported to dramatically alter SNP array signals
and complicate accurate identification of aberra-
tions in cancer genomes. To address these issues,
we propose a novel Global Parameter Hidden
Markov Model (GPHMM) to unravel tangled
genotyping data generated from tumor samples. In
contrast to other HMM methods, a distinct feature
of GPHMM is that the issues mentioned above are
quantitatively modeled by global parameters and
integrated within the statistical framework. We
developed an efficient EM algorithm for parameter
estimation. We evaluated performance on three data
sets and show that GPHMM can correctly identify
chromosomal aberrations in tumor samples con-
taining as few as 10% cancer cells. Furthermore,
we demonstrated that the estimation of global par-
ameters in GPHMM provides information about the
biological characteristics of tumor samples and the
quality of genotyping signal from SNP array experi-
ments, which is helpful for data quality control and
outlier detection in cohort studies.
INTRODUCTION
One critical feature of cancer genomes is chromosomal
aberrations (1). Recurrent genomic aberrations such as
copy number gain or loss and loss of heterozygosity
(LOH), are often associated with inappropriate expression
of oncogenes, tumor suppressor genes, and genes that are
involved in cancer development (2). Relationships between
clinical outcome and chromosomal aberrations have been
established based on the association of either individual
genomic abnormalities such as ampliﬁcation of HER2
(ERBB2) and MYCN (1) or distinct patterns of chromo-
somal abnormalities from whole genome proﬁling (3).
Emerging data on the genetic makeup of breast cancers
show that particular regions of the genome are commonly
ampliﬁed and these regions contain genes that drive cancer
progression. The best example of an important ampliﬁed
region is the 17q12 amplicon that harbors the HER2
oncogene. This amplicon leads to a more aggressive type
of tumor, which is now the target of a highly successful
antibody therapy, trastuzumab (Herceptin). Several
genes have been mapped to the HER2 amplicon based
on co-expression and close proximity to the HER2 gene
(4–7). It has been observed that RNAi knockdown of
coampliﬁed genes within the 17q12 amplicon resulted in
decreased cell proliferation and increased apoptosis (8).
Therefore, the 17q12 amplicon encodes a concerted
genetic program that contributes to tumor phenotype.
Clinically, cytogenetic technologies such as ﬂuorescence
in situ hybridization (FISH) have been successfully used to
detect chromosomal aberrations in cancer cells (1).
Cytogenetic technologies do not allow high resolution
genome-wide analysis, and for this reason array compara-
tive genomic hybridization (aCGH) was developed, ﬁrst
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probes (10). The introduction of single nucleotide poly-
morphism (SNP) genotyping arrays for copy number
analysis is a major advance because they allow for simul-
taneous detection of copy number and allelic imbalance
(including LOH) with high resolution. SNP arrays from
two platforms, Affymetrix (11) and Illumina (12), have
been widely adopted because of their high quality and
number of probes. Despite the technical difference
between these two platforms, it is suggested that similar
algorithms can be applied if raw data from Affymetrix
SNP arrays can be converted into the log R ratio (LRR)
and B allele frequency (BAF) signals that are used in the
Illumina platform when accompanied by appropriate nor-
malization and transformation (13,14).
Though various computational methods have been
proposed for automatic detection of copy number
change or LOH from SNP array data (13–25), many of
these methods are not speciﬁcally designed to study
chromosomal aberrations in cancer genomes, and do not
address some critical issues that have been encountered in
previous studies of tumor samples (13,15,22,24,25).
Speciﬁcally, recent studies (24,25) have shown that in
SNP-array experiments, sample DNA is treated as if it
has an approximate normal (near diploid) genome and
therefore the normalized intensity signals may fail to cor-
rectly indicate the underlying aneuploidy in cancer cells.
From LRR signals alone, cancer cells with a complete
triploid genome cannot be distinguished from those with
a normal diploid genome. To address this issue, new algo-
rithms such as OverUnder (24) and GAP (25) have been
proposed to correct erroneously-shifted LRR signal
baseline. These algorithms are designed to infer copy
number not only from total signal intensity but also
allelic imbalance information. OverUnder examines the
LRR distribution in regions with discriminative patterns
observed from BAF signals; for example, a BAF stretch
centering on 0.5 indicates even-numbered copy number
(24). For Affymetrix platform, Greenman et al. (26)
introduced a preprocessing transformation and hidden
Markov model algorithm referring to aneuploid cancer
samples. These approaches advanced our understanding
of the systematic bias in SNP-array data for complex
tumor samples.
Another issue in identiﬁcation of chromosomal aberra-
tions in cancer cells comes from the fact that biopsies ex-
tracted from a tumor usually contain normal, non-tumor
cells (such as stroma and lymphocytes), which may lead to
a dramatic alteration of both LRR and BAF signals
generated from SNP array experiments. It has been
reported that a small amount of normal cells admixed
with tumor cells can be helpful for identifying somatic
deletions (15,22). On the other hand, an increase in the
proportion of normal stromal cells in a tumor sample will
make both LRR and BAF signals converge to the typical
pattern of a diploid genome (23). In other words, normal
cell contamination decreases the signal-to-noise ratio in
SNP array experiments and chromosomal aberrations
can eventually become undetectable when normal cells
dominate in a biopsy. Some studies attempted to solve
this problem by modeling the dynamic patterns of both
LRR and BAF signals in contaminated tumor samples
(13,15,22,23,25). For example, SiDCoN provides empiric-
al formulas of LRR/BAF signals in the presence of
normal cell contamination (23). The formulas used for
BAF signals were later shown to be identical to those
adopted in the BAFsegmentation method (15), which was
developed to detect LOH and allelic imbalance in cancer
cells using only BAF signals. Recently, Sun et al. (13)
proposed a different approach to solve this problem.
They argued that a HMM with ﬁxed parameters for
copy number variation, as used in PennCNV (14), are in-
appropriate for analyzing tumor samples. Instead,
sample-speciﬁc HMMs are required due to the varying
proportions of normal cell contamination in tumor
samples. Therefore they introduced an HMM named
genoCNA, which is based on traditional continuous
HMMs with a training procedure for parameter
estimation.
There is another important issue in the assessment of
SNP array data. Diskin et al. (27) identiﬁed genomic
waves in both Illumina and Affymetrix platforms, which
may prevent accurate inference of copy number changes.
They further demonstrated that the wavy effects in LRR
signals best correlate with GC content and proposed a
linear regression model to correct GC content bias.
However, an underlying assumption of this model is that
SNPs used for regression should have the same copy
number since copy number is the most inﬂuential factor
in determining LRR signals. As a result, this model is
suitable for normal genomes with sparse copy number al-
teration events but may not work well for tumor samples
with widespread chromosomal abnormalities.
Critically, all the aforementioned issues strongly affect
each other and will dramatically complicate determination
of copy number and LOH if they occur in the same
sample. For example, the OverUnder method for LRR
signal shift in aneuploid tumors may fail because of
altered patterns of BAF signals caused by normal cell con-
tamination. Likewise, approaches to determine the normal
cell proportion from altered BAF signals or to adjust GC
content bias may also fail as copy number cannot be
directly inferred from LRR signals if there is an erroneous
baseline shift due to aneuploidy. Finally, failure to quan-
titatively measure the effect of LRR signal shift due to
aneuploidy, normal cell contamination, and GC content
bias will hamper correct identiﬁcation of copy number
change and LOH in cancer genomes. Therefore it is pref-
erable that all these issues can be integrated together based
on their empirical models suggested in (15,17,22,23,25,27)
and then addressed simultaneously in a detection method.
For example, using the dynamic model of LRR/BAF
signals that has been validated in refs. (15,25), Popova
et al. (25) pioneered a pattern recognition approach that
ﬁrst models a Genome Alteration Print (GAP) template
parameterized with LRR baseline shift and the proportion
of normal cells, and then by performing an exhaustive
search of all parameter conﬁgurations, identify all
feasible GAP templates from which the best interpretation
is chosen based on pre-deﬁned criteria. By modeling and
solving these two issues simultaneously, this method
Nucleic Acids Research, 2011,Vol.39, No. 12 4929demonstrates better performance than OverUnder on dif-
ferent data sets (25).
We have previously developed a HMM approach for
detection of tumor chromosomal aberrations using SNP
array data which addresses some of these issues but
requires manual annotation of LRR shift and proportion
of normal cells (28). In this study, we introduce a novel
method, named Global Parameter Hidden Markov Model
(GPHMM), which automatically dissects copy number al-
teration and LOH in SNP array data from tumor sample
DNA. Instead of trying to separately address each of the
complicating issues discussed above, we propose new ob-
servation probability density functions (pdfs) to allow
quantitative modeling of all these issues together. Similar
to the intent of GAP, GPHMM provides a comprehensive
description of the statistical distributions of genotyping
signals from tumor samples and a novel approach to
address these issues by incorporating them into the
HMM statistical framework. GPHMM provides not
only improved solutions to these issues but also automatic
and accurate identiﬁcation of copy number and LOH
status of each SNP in the assay.
METHODS
Deﬁnitions of hidden states
The deﬁnitions of the hidden states used in GPHMM are
shown in Table 1. Here, we use ‘A’ and ‘B’ to represent the
two SNP alleles inherited from parents. Different kinds of
chromosomal abnormalities such as copy number gain/
loss and LOH are modeled in this study. In addition we
use tumor and normal cell genotype pairs to illustrate the
intrinsic relationship between tumor genotype and the
genotype of normal cells admixed in tumor samples. For
example, (AAB, AB) represents the case that tumor
genotype is ‘AAB’ while the genotype of the normal cell
is ‘AB’. Certain constraints regarding these two genotypes
are assumed, which are similar to the assumptions
involved in the deﬁnition of hidden states used by
genoCNA (13). We assume that the tumor genotype is
derived from the genotype of normal cells; for example,
when the normal genotype is homozygous, the tumor
genotype can only be homozygous; when the normal
genotype is heterozygous, the tumor genotype can be
either heterozygous or homozygous. The maximal copy
number state modeled in this study is set to 5, given the
fact that due to saturation effects in array hybridization,
genotyping signals may not provide adequate discrimina-
tive power to detect the difference between hidden states
with copy number larger than or equal to 5. Furthermore,
a special hidden state denoted as 0, is employed to repre-
sent occasional signal ﬂuctuation. The effect of signal ﬂuc-
tuation is uniquely formulated (see next section for details)
and independent of other hidden states. whereas it is
instead modeled in the observation pdfs of the other
states in PennCNV (14) and genoCNA (13). Finally, to
avoid a possible overﬂow issue in practice, the copy
number of deletion of two copies is set to a small
positive number of 0.01.
Observation probability density functions
In this study, we propose new observation pdfs in
GPHMM that include different quantitative models of
the issues in tumor genotyping data analyses. We refer
to the parameters used in the observation pdfs as global
parameters. They are the key parameters of the proposed
statistical framework and essentially control the distribu-
tions of both LRR and BAF signals for all hidden states in
GPHMM. Five different global parameters are employed
in all: proportion of normal cells (denoted as ws), LRR
baseline shift (denoted as o), coefﬁcient of the GC content
of investigated SNPs (denoted as h), and the standard de-
viation of LRR and BAF signals (denoted as  l and  b,
respectively). These global parameters can be affected by
the genetic makeup of a tumor sample, characteristics of
chromosomal aberrations, quality of DNA mass, features
of SNP array platform, and other technical details during
experimentation.
Suppose that the LRR signal (representing the over-all
allele intensity) of the ith SNP in the array is li, then its
observation pdf for a hidden state c (except state 0, see
below) can be formulated as (here we simply assume all
hidden states in GPHMM have the same signal variance):
fl ijws,o,h, l,c ðÞ ¼
1
 l
 
li   2log10 yc=2 ðÞ +o+hgi
  
 l
  
: ð1Þ
Table 1. Deﬁnition of hidden states in GPHMM
State Copy number Allelic information Copy number alteration status (Tumor genotype, normal cell genotype)
0 N/A N/A Fluctuation effect (N/A, AA), (N/A, BB), (N/A, AB)
1 0 Deletion Deletion of two copies (N/A, AA), (N/A, BB), (N/A, AB)
2 1 LOH Deletion of one copy (A,AA), (B,BB), (A,AB), (B,AB)
3 2 Heterozygous Normal (AA,AA), (BB,BB), (AB,AB)
4 2 LOH Copy neutral with LOH (AA,AA), (AA,AB), (BB,BB), (BB,AB)
5 3 Heterozygous Three copies with duplication of one allele (AAA,AA), (BBB,BB), (AAB,AB), (ABB,AB)
6 3 LOH Three copies with LOH (AAA,AA), (AAA,AB), (BBB,BB), (BBB,AB)
7 4 Heterozygous Four copies with duplication of one allele (AAAA,AA), (BBBB,BB), (AAAB,AB), (ABBB,AB)
8 4 Heterozygous Four copies with duplication of both alleles (AAAA,AA), (BBBB,BB), (AABB,AB)
9 4 LOH Four copies with LOH (AAAA,AA), (BBBB,BB), (AAAA,AB), (BBBB,AB)
10 5 Heterozygous Five copies with duplication of one allele (AAAAA,AA), (BBBBB,BB), (AAAAB,AB), (ABBBB,AB)
11 5 Heterozygous Five copies with duplication of both alleles (AAAAA,AA), (BBBBB,BB), (AAABB,AB), (AABBB,AB)
12 5 LOH Five copies with LOH (AAAAA,AA), (BBBBB,BB), (AAAAA,AB), (BBBBB,AB)
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the GC content associated with the ith SNP (27) and the
logarithm part is adopted from the formula introduced in
ref. (23), in which a log-linear relationship between the
expected mean of LRR signal for each hidden state and
the corresponding average copy number. The average
copy number yc, is deﬁned as:
yc ¼ wsns+ð1   wsÞnc ð2Þ
Here ns and nc are the copy number of normal cell and the
copy number of tumor in state c, respectively. For
example, in the case of no normal contamination, the
average copy number of state 0 by Equation (2) is 0.01
and the expected theoretical LRR mean (suppose neither
GC content bias nor LRR baseline shift occurs) is  4.6,
which is consistent with the results reported in refs (23).
Using above formulas, the effects of LRR signal shift by
aneuploidy, normal cell contamination and GC content
bias are simultaneously modeled. As the intensity ratio
of two different alleles, BAF signals are not directly
affected by aneuploidy or GC content bias. However,
they are extremely sensitive to normal cell contamination.
Based on existing models described in refs (15) and (23),
we derive the pdf of the BAF signal for the ith SNP in
state c (c >1) as:
fb ijws, b,c ðÞ ¼
X gc
k¼1
p0 k ðÞ
1
 b
 
bi  
wsns
yc usk+
1 ws ðÞ nc
yc uck
  
 b
0
@
1
A:
ð3Þ
Here gc is the number of genotype pairs included in state c.
p0 k ðÞ is the prior probability of observing genotype pair k,
which is estimated from the BAF in the normal population
(14), with respect to the genotype of the normal cell in the
genotype pair. usk and uck are the theoretical means of
BAF signals for normal and pure tumor cells, respectively,
in genotype pair k. For example with c ¼ 5 and k ¼ 4,uck
represents the mean value of tumor BAF signals for the
forth genotype pair in state 5 [i.e. (ABB, AB), see in
Table 1], which is deﬁned as 0.667 in this study. The
implementation of GPHMM, Equation (3), is further
simpliﬁed by using mirrored BAF signals (equal or
greater than 0.5), which requires fewer genotype conﬁgur-
ations (15). For example, in state 3 only two genotype
pairs: (BB, BB) and (AB, AB) are required after this trans-
formation. Finally, it should be pointed out that, due to
the concern of model simplicity and computational cost,
the effect of BAF signal truncation investigated in ref. (13)
is not taken into account in Equation (3).
For SNPs in state 0, information about tumor genotype
is not available from SNP-array experiments. Therefore a
uniform distribution is employed to approximate the pdfs
of LRR and BAF signals:
fl ijc ðÞ ¼
1
b a, for a   li   b
0, for li < a or li > b
 
, ð4Þ
fb ijc ðÞ ¼
1
b0 a0 , for a0   bi   b0
0, for bi < a0 or bi > b0
 
ð5Þ
In this study, a, b are set to  5, 5 for LRR, and, a0, b0, are
set to 0, 1 for BAF.
EM algorithm for GPHMM
For canonical HMMs, algorithms for parameter estima-
tion have been proposed and successfully applied in ﬁelds
such as speech recognition (29). In this study, we propose
an EM algorithm (30) specially designed for GPHMM to
update the global parameters in the algorithm. As sug-
gested in ref. (30), for ﬁnite mixtures we can estimate
global parameters using only partial log-likelihood func-
tions. Speciﬁcally, in the nth iteration of the EM algo-
rithm, given the LRR data we can formulate the partial
log-likelihood as:
LLl ¼
X N
i¼1
X C
c¼1
Iii c ðÞ log fl ijws,o,h, l,c ðÞ ðÞ : ð6Þ
Here, li is the observed LRR value of the ith SNP and Ii c ðÞ
is an indicator function with value 1 if the ith SNP is in
state c in tumor cells and value 0 otherwise. C is the total
number of hidden states. In the expectation step of the
EM algorithm, the expectation of the partial
log-likelihood for LRR data is formulated as:
EL L l ðÞ ¼
X N
i¼1
X C
c¼1
 
n ðÞ
i c ðÞ log fl ijws;o;h;  l;c ðÞ ðÞ
¼
X N
i¼1
X C
c¼1
 
n ðÞ
i c ðÞ log
1
ﬃﬃﬃﬃﬃﬃ
2 
p
    
 log  l ðÞ  
li   2log10 yc=2 ðÞ þ o þ hgi
      2
2  l ðÞ
2
!
:
ð7Þ
Here  
n ðÞ
i c ðÞis the posterior probability of the ith SNP to
be in state c, which can be calculated by the forward–
backward algorithm (29). Similarly, we can derive the ex-
pectation of the partial log-likelihood function for BAF
data as:
EL L b ðÞ ¼
X N
i¼1
X C
c¼1
 
n ðÞ
i c ðÞ fb ijws;  b;c ðÞ
¼
X N
i¼1
X C
c¼1
 
n ðÞ
i c ðÞ
X gc
k¼1
p0 k ðÞlog
1
ﬃﬃﬃﬃﬃﬃ
2 
p
  
  log  b ðÞ
 
 
bi   wsnsusk þ 1   ws ðÞ ncuck ðÞ =yc ðÞ
2
2  b ðÞ
2
 
:
ð8Þ
Here bi is the observed BAF signal of the ith SNP. In the
maximization step of the EM algorithm, we adopted the
coordinate ascent algorithm, to increase the expectation of
total partial log-likelihood which is the sum of the
right-hand sides of Equations (7) and (8), with respect to
different global parameters. First, we select o and replace
the other global parameters with the corresponding values
obtained from the previous iteration. By taking the partial
derivative with respect to o and setting it to 0, we derive
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next iteration:
o n+1 ðÞ ¼
PN
i¼1
PC
c¼1  
n ðÞ
i c ðÞli   2log10 y n ðÞ
c =2
  
+h n ðÞ gi
     
PN
i¼1
PC
c¼1  
n ðÞ
i c ðÞ
ð9Þ
with
y n ðÞ
c ¼ w n ðÞ
s ns+1  w n ðÞ
s
  
nc: ð10Þ
Similarly, we update h n+1 ðÞ , 
n+1 ðÞ
l and  
n+1 ðÞ
b by
h n+1 ðÞ ¼
PN
i¼1
PC
c¼1  
n ðÞ
i c ðÞ gi li   2log10 y n ðÞ
c =2
  
+o n+1 ðÞ      
PN
i¼1
PC
c¼1  
n ðÞ
i c ðÞ g2
i
,
ð11Þ
 
n+1 ðÞ
l ¼
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
PN
i¼1
PC
c¼1  
n ðÞ
i c ðÞli  2log10 y
n ðÞ
c =2
  
+o n+1 ðÞ +h n+1 ðÞ gi
      2
PN
i¼1
PC
c¼1  
n ðÞ
i c ðÞ
v u u u t ,
ð12Þ
 
nþ1 ðÞ
b ¼
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
PN
i¼1
PC
k¼1  
n ðÞ
i c ðÞ
n
Pgc
k¼1 p0 k ðÞbi   w n ðÞ
s nsusk þ 1   w n ðÞ
s
  
ncuck
  
=y n ðÞ
c
   2o
PN
i¼1
PC
c¼1  
n ðÞ
i c ðÞ
v u u u u u u t :
ð13Þ
Finally, we focus on the expected likelihood in Equation
(13) for updating global parameter ws, since it has been
shown (15,23) that BAF signals are very sensitive to
normal cell contamination. They, therefore, can alone
provide sufﬁcient information for accurate inference of
normal cell proportion if information about the copy
number states is available (in this setting copy number
information is obtained from  
ðnÞ
i ). Using the strategy
described above, we obtain the following formula to
update ws by replacing yðn+1Þ
c with  ðnÞ
c in this procedure:
w nþ1 ðÞ
s ¼
PN
i¼1
PC
c¼1  
n ðÞ
i c ðÞ
n
Pgc
k¼1 p0 k ðÞnsusk   ncuck ðÞ bi   ncuck=y n ðÞ
c
  
=y n ðÞ
c
 
PN
i¼1
PC
c¼1  
n ðÞ
i c ðÞ
Pgc
k¼1 p0 k ðÞ nsusk   ncuck ðÞ =y
n ðÞ
c
   2 :
ð14Þ
The algorithm is constrained to identify ws in the interval
of [0 0.9], so if w n+1 ðÞ
s is less than 0 or greater than 0.9, it
will be set to 0 or 0.9, respectively. We note that the closed
form in Equation (14) only provides an approximate
solution even though it works well in practice.
Alternatively, some numerical methods, e.g. Newton–
Raphson method (31), can also be adopted in GPHMM
for estimating ws
For estimation of state transition matrix A and initial
state distribution  , we use the standard approach dis-
cussed in ref. (29) since it is unrelated to the global par-
ameters. In practice, the EM algorithm for GPHMM is
implemented as follows: (i) start with initial parameters
(  0 ðÞ ,A 0 ðÞ ,o 0 ðÞ ,h 0 ðÞ ,w 0 ðÞ
s , 
0 ðÞ
l , 
0 ðÞ
b ) and calculate intermedi-
ate parameters  
1 ðÞ
i using the standard forward-backward
algorithm, (ii) update  1,A 1 ðÞ ,o 1 ðÞ ,w 1 ðÞ
s , 
1 ðÞ
l , 
1 ðÞ
b using the
aforementioned method, (iii) repeat steps 1 and 2 until the
algorithm converges. Once this training procedure is
ﬁnished, the global parameters in the last iteration will
be output as the optimal estimators. At the same time,
genotype, copy number and LOH status for each probe
in SNP array can be inferred from the hidden state
associated with the largest posterior probability.
Initialization of parameters
In this study, probabilities of initial states in GPHMM are
pre-deﬁned using the following formula:
  0 ðÞ¼  i fg , i ¼
1 pf
N 1, for c > 0
pf, for c ¼ 0
  
: ð15Þ
Here N is the number of hidden states deﬁned in
GPHMM. The initial value for probability of ﬂuctuation
pf is set to a small value of 10
 4. For other states, the
initial values are set to be the same, i.e. no prior informa-
tion. As for the state transition probabilities, the initial
values are determined as follows:
Að0Þ¼ aij
  
,aij¼
1   pt   pf,
pt= N   2 ðÞ ,
pf,
1   pf
  
= N   1 ðÞ ,
for i ¼ j,i > 0,j > 0
for i 6¼ j,i > 0,j > 0
for j ¼ 0
for i ¼ 0,j > 0
8
> > <
> > :
9
> > =
> > ;
:
ð16Þ
pt is the initial transition probability between two different
non-ﬂuctuation states, which is set to be 10
 5 in this study.
Initial values of the global parameters h,  l and  b are set
to 0, 0.2 and 0.03, which are the expected values of normal
SNP array data with good genotyping signal quality,
based on our data quality control analysis of various
SNP array datasets (data not shown). Moreover, our
analyses suggest that the appropriate initial values of the
global parameters o and ws are necessary for modeling
training, therefore a simple grid search (31) of these two
parameters is adopted in GPHMM in order to ﬁnd
optimal initial parameters.
Implementation of GPHMM
An efﬁcient implementation of GPHMM using Matlab/C
is available at: http://genecube.med.yale.edu:8080/
GPHMM. Information about the GC content and BAF
for each SNP probe is obtained from the PennCNV
package (14). It generally takes less than 10min to run a
Human 610-Quad ( 610 000 SNP probes) sample using a
standard desktop PC with 2.33GHz CPU and 2G RAM.
This utility provides not only accurate prediction of
genotype, copy number and LOH status of each SNP
probe, but also estimation of global parameters as well
as other information such as the proportion of abnormal
chromosomal regions in cancer genome and tumor cell
DNA index. It also includes a function that can be used
to visualize LRR/BAF signals and copy number/LOH
results.
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Fresh tumor core biopsies were taken before and at a 2
week time point after a single dose of trastuzumab (T)
(8mg/m
2) from 80 HER2-overexpressing, early breast
cancer patients enrolled on a clinical trial of trastuzumab
and chemotherapy. Nucleic acids were extracted from 109
core biopsies using a Qiagen AllPrep kit (Qiagen,
Valencia, CA, USA). DNA was analyzed with the
Human 610-Quad (v1.0) DNA Analysis BeadChip Kits
(Illumina Inc., San Diego, CA, USA) with the assistance
of the W. M. Keck Foundation Microarray Resource
(New Haven, CT, USA). Normalized intensity signals
were generated from the Illumina BeadStudio utility and
then processed by tQN (32) in order to remove possible
asymmetry in BAF signals.
FISH
Tissue preparation and FISH was performed using the
manufacturer’s guidelines (Vysis, Abbott Molecular,
Downers Grove, IL, USA). Sections were deparafﬁnized
with Xylenes and pretreated with the Vysis Pretreatment
Kit II. The LSI TOP2A Spectrum Orange/HER2/neu
Spectrum Green/ CEP 17 Spectrum Aqua Probe;
ProVysion
TM Multi-color Probe; LSI Cyclin D1
Spectrum Orange/CEP 11 Spectrum Green Probe was
used for hybridizations. Co-denaturation of the probes
and tissues was done on a ThermoBrite (Abbott
Molecular) at 75 C for 6min and hybridization at 39 C
for 17–19h. Rapid wash protocol was used. At least 20
tumor cells (range of 20–80 cells) were enumerated.
RESULTS
Dilution series data
We ﬁrst tested the performance of GPHMM on a dilution
series of breast cancer/normal cell lines admixed with
known proportions of cancer cell DNA (15). The
genomic DNA from an aneuploid cancer cell line
(ATCC: CRL-2324D) was mixed in 0–0.9 proportion
with DNA from a normal cell line (ATCC: CRL-2325D)
and then hybridized to Illumina Human370K BeadChips.
Genotyping data for each sample was examined before
testing, and large regions of heterozygous deletion on
chromosomes 6 and 16 of the normal cell line were
identiﬁed (Supplementary Figure S1) and removed from
further analysis. All of the mixture samples as well as
the cancer cell line were run against GPHMM, and the
estimated global parameters are show in Table 2. The
standard deviations of LRR/BAF signals ( l and  b) for
different dilution samples are close to the initial values of
0.2 and 0.03, indicating that all of these samples have good
signal quality. Coefﬁcients of GC content (h) for different
dilution samples are shown to have small absolute values,
suggesting there are no signiﬁcant GC content bias in this
data set. These results are consistent with our ﬁnding in
manual inspection of the genomic plots of BAF and LRR.
On the other hand, we found a strong correlation (correl-
ation coefﬁcient >0.98) between LRR signal shift and the
proportion of normal cell DNA (Figure 1). The most sig-
niﬁcant LRR signal shift occurred in the pure cancer cell
line DNA. With the percentage of normal cell DNA
increasing, the overall aneuploidy in the mixed sample
diminishes and LRR shift tends to decrease correspond-
ingly. When the proportion of normal cell reaches to 0.9,
the LRR baseline shift identiﬁed by GPHMM becomes
barely above zero. These results provide additional
support that cancer aneuploidy leads to LRR baseline
shift in SNP array experiments (24). Furthermore, we
examined the estimated ws by GPHMM and compared
them with the actual proportions used on the SNP
arrays. As shown in Table 2, the global parameter ws
estimated by GPHMM is close to the true normal cell
DNA proportion at different dilution levels. For
example, in mixed sample ‘CRL2324_10pc_Tum’ which
is dominated by normal cell and includes only 10%
cancer cell DNA, GPHMM can still accurately determine
the proportion of normal cell DNA from the extremely
weak signals of chromosomal aberration. Analyses of the
global parameters provide useful information about SNP
array experiments such as quality of genotyping signal and
the genetic makeup of a mixed sample. In comparison,
GAP can also correctly estimate low and medium propor-
tions of normal cell DNA in admixed samples, but fails to
recognize high normal contamination in samples
‘CRL2324_10pc_Tum’ and ‘CRL2324_14pc_Tum’ by in-
correctly treating them as pure diploid samples.
Table 2. Comparison of normal DNA proportions estimated by different methods on dilution series data
Sample GPHMM GAP p Normal DNA
proportion
oh  l  b ws
CRL2324_10pc_Tum 0.011 0.027 0.20 0.02 0.90 0.01 0.90
CRL2324_14pc_Tum  0.009 0.019 0.19 0.02 0.88 0.01 0.86
CRL2324_21pc_Tum  0.016 0.023 0.20 0.03 0.81 0.84 0.79
CRL2324_23pc_Tum  0.067 0.023 0.23 0.03 0.69 0.73 0.77
CRL2324_30pc_Tum  0.046 0.022 0.18 0.03 0.72 0.75 0.70
CRL2324_34pc_Tum  0.058 0.026 0.23 0.03 0.68 0.72 0.66
CRL2324_45pc_Tum  0.069 0.016 0.22 0.03 0.63 0.66 0.55
CRL2324_47pc_Tum  0.102 0.042 0.22 0.03 0.55 0.58 0.53
CRL2324_50pc_Tum  0.102 0.031 0.25 0.03 0.57 0.59 0.50
CRL2324_79pc_Tum  0.189 0.032 0.24 0.03 0.19 0.20 0.21
CRL2324  0.283 0.024 0.24 0.02 0.02 0.00 0.00
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further evaluate the efﬁciency of GPHMM. Two state of
the art methods, genoCNA (version: 1.0.8 with default
parameters, no normal tissue genotypes are used) and
GAP, were also employed for comparison. A simple but
efﬁcient measurement to evaluate the prediction perform-
ance of different methods using dilution series samples is
the self-consistency of the results from different dilution
samples, with respect to the predicted results of the pure
cancer cell line DNA. We calculated the self-consistency
percentages based on the predicted results of LOH state,
copy number, copy number and LOH state (Figure 2). To
make a fair comparison, we grouped results with copy
number  4 since genoCNA only identiﬁes genotypes
with a maximal copy number of 4. GPHMM consistently
demonstrates the best performance and a signiﬁcant ad-
vantage over genoCNA and GAP when there is 50% or
more normal cell in a mixed sample. For example, even
with only 10% cancer cell DNA, >80% of the LOH as-
signments by GPHMM are consistent with the results
from the pure cancer cell line, which is  40% higher
than the self-consistency obtained by genoCNA and
GAP. The self-consistency for GPHMM is 57% for
copy number state prediction, which is >15% higher
than the scores by genoCNA and GAP. When both
copy number and LOH states are considered, signiﬁcant
reduction in self-consistency is observed for both
genoCNA and GAP, suggesting that only a small part
of the whole cancer genome is perfectly identiﬁed,
whereas GPHMM retains the same good performance.
An example illustrated in Figure 3 further validates the
efﬁciency of GPHMM. It shows the genotyping signals
and assignment by GPHMM for two adjacent LOH
regions with different copy number on chromosome 17.
With the increase of normal cell proportion, BAF signals
representing different genotype pairs are dramatically
altered. At the same time, the difference of LRR signals
between two and three copies diminishes steadily.
Figure 2. Comparison of the self-consistency percentages for different
methods. (a) Self-consistency percentages based on LOH status.
(b) Self-consistency percentages based on copy number state.
(c) Self-consistency percentages based on both copy number and
LOH states.
Figure 1. Strong correlation observed between proportion of normal
cell and LRR signal shift in dilution series data. The empirical regres-
sion function is also shown in the ﬁgure.
4934 Nucleic Acids Research, 2011,Vol.39, No. 12However, both copy number and LOH assignments are
very consistent throughout all four samples as well as
other samples in the dilution series data (Supplementary
Figure S2). For comparison, we also plotted the results of
genoCNA and GAP and showed them in Supplementary
Figures S3 and S4. GenoCNA is not speciﬁcally designed
for aneuploid samples and for this reason failed to cor-
rectly identify these chromosomal aberrations in most of
the dilution series samples and the results throughout dif-
ferent samples are rather discrepant. This indicates that
SNP-array data generated from aneuploid cancer
samples signiﬁcantly differs from diploid cancer samples
and the issue introduced by aneuploidy should be carefully
addressed in any method for cancer SNP-array data
analysis. Also, it should be pointed out that we did not
include genotyping information for the matched normal
Figure 3. Plots of LOH regions on chromosome 17 and the results of GPHMM for dilution series data. (a) Plot of sample ‘CRL2324’ (100% cancer
cell DNA). Typical LOH patterns are observed in this pure cancer cell line and there is a signiﬁcant difference in LRR signals for two LOH regions.
(b) Plot of sample ‘CRL2324-50pc-Tum’ (50% cancer cell DNA). Due to normal cell contamination, two additional BAF bands and reduction in
difference in LRR signals are observed whereas the results of GPHMM remain the same. (c) Plot of sample ‘CRL2324-14pc-Tum’ (14% cancer cell
DNA). The results of GPHMM keep unchanged with the increase of normal cell proportion. (d) Plot of sample ‘CRL2324-10pc-Tum’ (10% cancer
cell DNA). With 90% of normal cell, the patterns of BAF and LRR signals are barely discernible. However, GPHMM can still accurately identify
these two LOH regions.
Nucleic Acids Research, 2011,Vol.39, No. 12 4935tissue that can be used in genoCNA, in order to compare
the three methods and to illustrate the effect of the
baseline shift in LRR signals caused by aneuploidy. On
the other hand, the results of GAP have very good agree-
ment with those obtained by GPHMM in the pure cancer
cell line data. GAP can also detect most of the LOH
region when normal cell proportion is no more than
0.66. However, the assignment of copy number state by
GAP seems to be sensitive to experimental noise. For
example in sample ‘CRL2324_45pc_Tum’ with 45% of
cancer cell DNA, GAP provides correct assignment of
copy number for the majority of these two regions.
However, for sample ‘CRL2324_47pc_Tum’ with approxi-
mately the same percentage of cancer cell DNA, the
results of GAP become inconsistent. In samples with
normal cell proportion >0.66, large blocks of chromo-
somal regions with inconsistent LOH/copy number
assignment are observed in Supplementary Figure S4.
GAP data
In the recent study of Popova et al. (25), 40 breast cancer
samples were proﬁled using 300K Illumina SNP-arrays
(Human Hap300-Duo). Furthermore, the DNA indices
of 18 samples obtained by ﬂow cytometry (FCM) are
reported to be very close to the estimated DNA indices
by GAP. To test whether other methods can also provide
accurate estimation, we downloaded the SNP array data
of these 18 samples and performed analyses using
GPHMM and genoCNA. First, whole genomic data for
each sample was plotted and manually inspected, and
most of them are shown to have good data quality. For
example the plot of sample ‘BLC_B1_T19’
(Supplementary Figure S5) exhibits very clear LRR/BAF
patterns throughout the whole genome, indicating
high-quality of genotyping signals. This conclusion is
also supported by the LRR/BAF standard deviations
estimated by GPHMM (Table 3). However, samples
‘BLC_B1_T14’, ‘BLC_B1_T17’ and ‘BLC_B1_T22’, have
substantially increased noise in both LRR and BAF
signals (Supplementary Figure S5), and the corresponding
 l and  b estimated by GPHMM are 0.42, 0.65, 0.46
and 0.06, 0.06, 0.05, respectively (Table 3). These noisy
samples can be easily identiﬁed from the histograms
of these two global parameters (Supplementary
Figure S6), suggesting an efﬁcient way for outlier detec-
tion and quality control in batch analysis of SNP array
data.
Next, we estimated the DNA indices from the results of
the GPHMM and GAP by following the approach in (25)
and compared them with the experimental results from
FCM analysis (Table 3). Both methods provide good pre-
diction of DNA index and similar estimations of normal
cell proportion for the samples in this data set except for a
few discordant cases. For example, similar to the previ-
ously discussed results by GAP (25), DNA indices of
‘BLC_B1_T22’ and ‘BLC_34’ predicted by GPHMM are
around 1, suggesting approximately diploid genomes.
However, the DNA indices determined by FCM indicate
cancer chromosomes in these samples are near tetraploid.
Another case is tumor sample ‘BLC_T15’, for which
GPHMM and GAP have different estimations with
diverging tendencies. The DNA index of 1.68 predicted
by GPHMM suggests the cancer genome is largely
ampliﬁed, while the experimental result (1.11 by FCM)
indicates it is only moderately duplicated. At the same
time, GAP has an estimated DNA index of only 0.89
and reports many deleted chromosomal regions in the
results.
The discrepancy between the results of FCM analysis
and these two computational methods may actually be
caused by tumor sub-clonal losses that are erroneously
assigned as three copies in these samples. Therefore
further experimental study is required to validate the pre-
diction results as previously suggested (25).
Table 3. Comparison of tumor DNA indices estimated by different methods on GAP data
Sample GPHMM GAP FCM
oh  l  b ws DNA index p DNA index DNA index
BLC_B1_T14  0.38 0.005 0.42 0.06 0.15 1.61 0.15 0.85 1.14
BLC_B1_T17 0.04 0.080 0.65 0.06 0.30 0.84 0.23 0.82 0.84
BLC_B1_T19  0.18  0.013 0.18 0.03 0.55 1.56 0.60 1.63 1.60
BLC_B1_T20  0.11 0.003 0.18 0.03 0.59 1.39 0.60 1.48 1.41
BLC_B1_T22 0.07 0.047 0.46 0.05 0.09 0.94 0.13 0.94 1.98
BLC_T07  0.15 0.012 0.18 0.03 0.56 1.45 0.56 1.49 1.68
BLC_T09  0.40 0.006 0.22 0.03 0.02 1.70 0.08 1.85 2.02
BLC_T10  0.45 0.008 0.18 0.03 0.04 1.81 0.05 1.90 1.88
BLC_T12  0.20  0.003 0.19 0.03 0.35 1.48 0.35 1.54 1.51
BLC_T15  0.26  0.019 0.19 0.03 0.42 1.68 0.26 0.89 1.11
BLC_T23  0.09 0.029 0.21 0.03 0.57 1.34 0.59 1.39 1.32
BLC_T31  0.38  0.011 0.23 0.04 0.07 1.72 0.16 1.84 1.91
BLC_T34 0.08 0.003 0.24 0.03 0.09 0.98 0.13 0.99 1.55
BLC_T37  0.23  0.051 0.26 0.04 0.08 1.44 0.11 1.53 1.51
L_B1_T24B  0.18  0.028 0.21 0.03 0.42 1.50 0.41 1.64 1.84
L_B1_T25A 0.00  0.032 0.17 0.03 0.58 1.00 0.61 1.04 1.00
L_B1_T30  0.39  0.005 0.22 0.04 0.17 1.76 0.22 1.83 1.84
L_B1_T47 0.01  0.022 0.19 0.03 0.54 1.00 0.55 1.03 1.00
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In addition to the two public data sets discussed above, we
applied GPHMM to a SNP array data set from 109 fresh
tumor core biopsies that were taken before or after
systemic therapy in 80 HER2-overpressing (deﬁned as
IHC 3+by DAKO Herceptest or HER2:CEP 17 ratio of
>2.0) early breast cancer patients enrolled on a clinical
trial of preoperative therapy. Similar to a previous obser-
vation that  10% of breast cancers had genomic proﬁles
without discernible abnormalities (3), some of the samples
(13 of 109) exhibit no discernable genomic aberrations
along all chromosomes and therefore are not included
for further analysis in this study. We ﬁrst examined the
distribution of global parameters illustrated in Figure 4. In
a few samples of this data set, non-trivial GC coefﬁcients
are observed, suggesting GC content bias may be an issue
in these samples. For example, the tumor sample with the
largest absolute GC coefﬁcient (h= 0.108) exhibits sig-
niﬁcant GC content bias (shown in Supplementary
Figure S7a). After removing the bias of GC content
using the linear model described in Equation (1) with
the estimated coefﬁcient, the LRR signal becomes much
smoother, which further leads to smooth and consistent
assignments of both copy number and LOH states
(Supplementary Figure S7b). The majority of the
samples, however, have good signal quality based on the
distributions of the global parameters  l and  b (illustrated
in Figure 4). We also identiﬁed two outlier samples with
notable increase of noise in both LRR and BAF signals.
About 91% tumor samples (87 of 96) are mixed with
>50% normal cells, of which 60 have normal cell propor-
tions larger than 0.7, and 12 have normal cell proportions
greater than 0.85.
Since all of the tumor biopsies included in this cohort
were taken from HER2-positive breast cancers, it is im-
portant to show efﬁcient identiﬁcation of HER2 ampliﬁ-
cations in these samples using SNP array data. Based on
the results of GPHMM, the distribution of the maximal
copy number in the HER2 region (inferred from the
HER2 FISH probe used in this study) is illustrated in
Figure 5a. About 95% of the tumor samples (91 of 96)
are identiﬁed as HER2 ampliﬁed with copy number
greater than 2. The majority of the identiﬁed samples
(78%) are assigned with the maximum copy number
gain (ﬁve or more copies). Interestingly, we found that
the genomic patterns of chromosome 17 in most
HER2-positive cancers can be classiﬁed into three
categories based on the copy number assignments
provided by GPHMM (demonstrated in Figure 5b). One
common genomic pattern is an isolated narrow peak in the
HER2 locus with high-level copy number ampliﬁcation
(top of Figure 5b). In other tumors, HER2 ampliﬁcation
spans a much broader chromosomal region (middle of
Figure 5b). Finally, in a few cases, ampliﬁcation covers
the whole q arm of the chromosome (bottom of
Figure 5b). It is noteworthy that large shifts in the LRR
signals illustrated in Figure 5b are observed, indicating
that these samples would not be correctly classiﬁed as
HER2-positive cancer, if correction of LRR signal shift
is not performed.
Figure 4. Histograms of estimated global parameters for HER2-positive breast cancer data. Top left: (a) histogram of GC coefﬁcient h. Top
right: (b) histogram of normal cell proportion ws Bottom left: (c) standard deviation of LRR signal  l Bottom right: (d) standard deviation of
BAF signal  b.
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the results from GPHMM. Breast cancer tissue from one
patient (YBCID: 184) was prepared and hybridized with
three FISH probes speciﬁc for six loci: HER2
(17q11.2-q12), TOP2A (17q21-22), CCND1 (11q13),
ZNF217 (20q13.2), MYC (8q24) and LPL (8p22).
Moreover, the a satellite DNA sequences at the centro-
meric regions of chromosome 8, 11 and 17 were also
identiﬁed with chromosome enumeration probes (CEP).
Figure 6 shows the results from FISH experiments, for
example in Figure 6a the multicolor FISH probes
detected high level ampliﬁcation of the HER2 locus
(average copy number 23.1) and normal copy number of
both TOP2A locus and the centromeric DNA of chromo-
some 17, which are consistent with the maximal copy
numbers estimated by GPHMM (Figure 6d).
Furthermore, Figure 6b indicates that this tumor
actually consists of two different clonal subpopulations:
one is characterized by three copies of CCND1 locus and
two copies of the centromeric DNA of chromosome 11
(indicated by yellow arrow) and the other is shown to
have four copies of CCND1 locus and three copies of
the centromeric DNA (indicated by green arrow). In this
scenario, the genotyping signals are extremely complicated
because they are generated from a mixture of three kinds
of genotypes (two different tumor subpopulations and
normal cells). However, as shown in Figure 6d,
GPHMM can still correctly identify the copy numbers
of the ﬁrst tumor subpopulation and the result is close
to the copy numbers estimated by FISH, which are ap-
proximately the averaged copy numbers of all tumor
subpopulations. The FISH analysis on chromosome 8 is
quite similar: two different types of tumor cells can be
recognized in Figure 6c, and GPHMM provides correct
estimations of the copy numbers in one subpopulation and
the results are also close to the averaged copy numbers
determined by FISH. Based on these results and the fact
that the estimated proportion of normal cells in this tumor
sample is nearly 0.8, we conclude that GPHMM is effect-
ive for analyses of tumor SNP array data.
DISCUSSION
In this study, we introduced a novel hidden Markov model
for detection of chromosomal aberrations in tumor
samples using whole-genome SNP genotyping data. Our
proposed method demonstrates several advantages
compared with other methods. GPHMM is a novel
method elaborated to decode the extremely complicated
SNP-array signals generated from tumor samples, in
which analysis has been shown to be very sensitive to
normal cell contamination of a tumor biopsy
(13,15,22,23), different types of chromosomal aberration
(24,25), as well as other factors such as DNA quantity in
experimentation (27). A signiﬁcant difference between
GPHMM and previous HMM methods is that by taking
all these effects into account, new quantitative models
were employed as the observation density functions in
GPHMM, which provide more accurate and comprehen-
sive description of the statistical behavior of genotyping
signals generated from tumor samples. Second, these
models are automatically optimized in GPHMM during
the execution of the EM training algorithm. The global
parameters are estimated by ﬁtting these quantitative
models, and the state transition matrix and the initial
state distribution in the Markov chain of the GPHMM
model are updated simultaneously. These two parameter
estimation procedures cooperate together to maximize the
likelihood of the observed SNP-array data. Based on the
Figure 5. Identiﬁcation of HER2 ampliﬁcation in HER2-positive
breast cancer data. (a) Pie chart for the maximal copy numbers of
HER2 region estimated by GPHMM. CN <2: maximal copy number
<2; CN=2: maximal copy number equal to 2; CN=3: maximal copy
number equal to 3; CN=4: maximal copy number equal to 4; CN  5:
maximal copy number greater than or equal to 5. (b) Different genomic
patterns of HER2 ampliﬁcation identiﬁed in HER2-positive breast
cancer data, arrows indicate the HER2 locus on chromosome 17.
4938 Nucleic Acids Research, 2011,Vol.39, No. 12well-established theory of HMM and the EM algorithm,
GPHMM achieves superior performance in identiﬁcation
of chromosomal aberrations in the cancer genome. Its ad-
vantages are most pronounced when SNP-array data is
extremely contaminated by normal cells or considerably
shifted due to aneuploidy. Third, instead of updating in-
dividual mean and standard deviation for each hidden
state as in traditional continuous HMMs, the global par-
ameters shared by all hidden states are directly estimated
speciﬁcally for each sample, and therefore provide useful
information regarding the tumor sample and SNP array
experiment. Global parameters  l and  b estimate the
standard deviations of LRR and BAF signals that are
associated with the quality of genotyping data. Another
global parameter ws provides accurate estimation of the
proportion of admixed normal cells and allows a better
understanding of the genetic makeup of a tumor biopsy.
Moreover, LRR baseline shift o is correlated with the
overall aneuploidy in the tumor sample and GC coefﬁcient
h is an indicator of possible GC content bias in LRR
signals. Information obtained from these global
parameters can be used in the pre-processing procedure
of a cohort study and is especially helpful in data
quality control and outlier detection. Finally, as a
HMM approach our proposed method does not require
preliminary segmentation of genotyping data that is used
in ref. (25) as a part of overall ﬁtting procedure, and there-
fore is advantageous in ﬁtting extremely contaminated and
noisy samples. Taken together, these unique modeling and
optimizing strategies endow GPHMM with superior
performance.
In this study, we also made following assumptions and
simpliﬁcations in statistical modeling of GPHMM:
(i) there is a log-linear relationship between average
copy number and expected mean of LRR signals; (ii) all
hidden states deﬁned in GPHMM have the same signal
variance; (iii) possible truncations of BAF signals (13) are
not taken into account. These approaches can greatly
improve the robustness and computational efﬁciency of
our proposed model, and are advantageous for
challenging cancer samples with severe normal cell con-
tamination and samples with noisy genotyping signals
Figure 6. Validation of GPHMM results in HER2-positive breast cancer sample. (a) FISH image of HER2 (green), TOP2A (red) and CEP 17 (aqua)
probe signals in tumor sample nuclei. HER2 locus is highly ampliﬁed (average copy number 23.1). (b) FISH image of CCND1 (red) and CEP 11
(green) probe signals in tumor nuclei. Yellow and green arrows show two different tumor subpopulations. (c) FISH image of MYC (green), LPL
(red) and CEP 8 (aqua) probe signals in tumor sample nuclei. Yellow and green arrows show two different tumor subpopulations. (d) Comparison of
the copy numbers estimated from FISH probes and the results of GPHMM using SNP array data.
Nucleic Acids Research, 2011,Vol.39, No. 12 4939caused by aneuploidy and GC content bias. These as-
sumptions and simpliﬁcations may also reduce the sensi-
tivity of the detection algorithm and even become a
disadvantage for less challenging cancer samples with
only slight normal cell contamination and good
genotyping signals. However, with the cancer samples
we analyzed, even in the case that aforementioned as-
sumptions are considerably violated, e.g. data that has
different signal variance in some states or is inﬂuenced
by the effect of signal truncation, GPHMM can still
provide accurate prediction results. For example in
Supplementary Figure S8, we show the genotyping data
for chromosome 1 of sample ‘BLC_T100 in the GAP data,
which is complicated by both effects. The BAF signals of
two LOH regions on the left have smaller variances than
those of the heterozygous regions on the right, and are
very close to the boundaries, suggesting some of them
are probably truncated to 0 or 1, respectively. Although
the estimated global parameter  b may become inaccurate
in this case, the whole statistical framework including es-
timation of other global parameters is barely affected. The
estimated mean values of genotyping signals, calculated by
the empirical formulas in Equations (1) and (3), are
illustrated by the red lines in the two panels at the
bottom, which clearly demonstrate that GPHMM can
still precisely grasp the statistical characteristics of the
genotyping data and provides accurate information
about copy number and LOH status for every chromo-
somal region. This conclusion is also supported by the
summarized results from GAP and FCM analysis on
this sample (see in Table 3).
Quantitative SNP arrays generate high-resolution
genotyping data with total signal intensity as well as in-
formation about individual alleles. They therefore allow
accurate identiﬁcation of copy number change and LOH
in cancer genome by using both LRR and BAF signals.
Despite the success reported in this article and previous
studies, there are still some concerns about interpreting
SNP array genotyping data from tumor samples. One
concern is that chromosomal aberrations will not be cor-
rectly identiﬁed if global parameters and copy number/
LOH states cannot be uniquely determined. As we previ-
ously mentioned, there are >10% tumor samples with no
discernable chromosomal aberrations in the
HER2-positive breast cancer data. As pointed out by
Attiyeh et al. (24), due to the technical limitation of
SNP arrays, we cannot determine the proportion of
normal cells in these tumors. Therefore additional inves-
tigation by histopathological examination and other bio-
logical techniques such as FISH are necessary.
Another obstacle to the application of SNP arrays in
cancer research is tumor heterogeneity. Recently Navin
et al. (33) investigated genomic heterogeneity in breast
tumors and showed more than a half of the tumors
studied (11 of 20) were polygenomic tumors with
multiple clonal subpopulations. This discovery suggests
that tumor heterogeneity should not be ignored in inter-
preting tumor SNP array data. However, so far there are
few efﬁcient approaches for identiﬁcation of polygenomic
tumors using SNP arrays, since the genotyping signals
will then be representative of the variation of both
subpopulation genotypes and their proportions in the
tumor. As we showed in the analyses of HER2-positive
breast cancer data set, GPHMM provides reasonable es-
timations of the tumor subpopulation with the greatest
degree of copy number aberration, even though the
model is not speciﬁcally designed for polygenomic
tumors. This conclusion will still hold if there is another
tumor subpopulation that closely resembles normal cells
but has sparse focal abnormalities, except that in this case
estimation of normal cell proportion may be inaccurate
since there is little genomic information that can help to
distinguish these ‘normal-like’ tumor cells. Comprehensive
evaluation of the performance of GPHMM under the
effect of tumor heterogeneity is beyond the scope of the
current work. In fact, it is possible that tumor
subpopulations have distinct aberrations in the same
region, for example, that one tumor clone has ampliﬁca-
tion in a chromosomal region and another has deletion in
the same region. In this case, it is almost unsolvable to
elucidate the genotypes of all tumor subpopulations using
SNP array alone. Therefore additional experiments such
as FISH are required, especially to estimate small propor-
tion clonal populations (33). However, the results sug-
gest that GPHMM can provide reasonable estimates of
copy number for tumors with a low proportion of
polygenotypes.
SUPPLEMENTARY DATA
Supplementary Data are available at NAR Online.
ACKNOWLEDGEMENTS
The authors thank Drs Min Chen and Yunxiao He for
critical reading of the article.
FUNDING
Funding for open access charge: Department of Defense
(grant W81XWH-04-1-0549 to L.H.); Yale Center of
Excellence in Molecular Hematology P30 DK072442-03
NIDDK (to D.T. and V.S.); Susan G. Komen
Foundation (grant number FAS0703853 to D.L.).
Conﬂict of interest statement. None declared.
REFERENCES
1. Albertson,D.G., Collins,C., McCormick,F. and Gray,J.W. (2003)
Chromosome aberrations in solid tumors. Nat. Genet., 34,
369–376.
2. Bentires-Alj,M., Gil,S.G., Chan,R., Wang,Z.C., Wang,Y.,
Imanaka,N., Harris,L.N., Richardson,A., Neel,B.G. and Gu,H.
(2006) A role for the scaffolding adapter GAB2 in breast cancer.
Nat. Med., 12, 114–121.
3. Hicks,J., Krasnitz,A., Lakshmi,B., Navin,N.E., Riggs,M.,
Leibu,E., Esposito,D., Alexander,J., Troge,J., Grubor,V. et al.
(2006) Novel patterns of genome rearrangement and their
association with survival in breast cancer. Genome Res., 16,
1465–1479.
4. Jarvinen,T.A. and Liu,E.T. (2003) HER-2/neu and topoisomerase
IIalpha in breast cancer. Breast Cancer Res. Treat., 78, 299–311.
4940 Nucleic Acids Research, 2011,Vol.39, No. 125. Keith,W.N., Douglas,F., Wishart,G.C., McCallum,H.M.,
George,W.D., Kaye,S.B. and Brown,R. (1993) Co-ampliﬁcation
of erbB2, topoisomerase II alpha and retinoic acid receptor alpha
genes in breast cancer and allelic loss at topoisomerase I on
chromosome 20. Eur. J. Cancer, 29A, 1469–1475.
6. Smith,K., Houlbrook,S., Greenall,M., Carmichael,J. and
Harris,A.L. (1993) Topoisomerase II alpha co-ampliﬁcation with
erbB2 in human primary breast cancer and breast cancer cell
lines: relationship to m-AMSA and mitoxantrone sensitivity.
Oncogene, 8, 933–938.
7. Tanner,M., Isola,J., Wiklund,T., Erikstein,B., Kellokumpu-
Lehtinen,P., Malmstrom,P., Wilking,N., Nilsson,J. and Bergh,J.
(2006) Topoisomerase IIalpha gene ampliﬁcation predicts
favorable treatment response to tailored and dose-escalated
anthracycline-based adjuvant chemotherapy in HER-2/
neu-ampliﬁed breast cancer: Scandinavian Breast Group Trial
9401. J. Clin. Oncol., 24, 2428–2436.
8. Kao,J. and Pollack,J.R. (2006) RNA interference-based functional
dissection of the 17q12 amplicon in breast cancer reveals
contribution of coampliﬁed genes. Genes Chromosomes Cancer,
45, 761–769.
9. Solinas-Toldo,S., Lampel,S., Stilgenbauer,S., Nickolenko,J.,
Benner,A., Dohner,H., Cremer,T. and Lichter,P. (1997)
Matrix-based comparative genomic hybridization: biochips to
screen for genomic imbalances. Genes Chromosomes Cancer, 20,
399–407.
10. Park,P.J. (2008) Experimental design and data analysis for array
comparative genomic hybridization. Cancer Invest., 26, 923–928.
11. McCarroll,S.A., Kuruvilla,F.G., Korn,J.M., Cawley,S., Nemesh,J.,
Wysoker,A., Shapero,M.H., de Bakker,P.I., Maller,J.B., Kirby,A.
et al. (2008) Integrated detection and population-genetic analysis
of SNPs and copy number variation. Nat. Genet., 40, 1166–1174.
12. Peiffer,D.A., Le,J.M., Steemers,F.J., Chang,W., Jenniges,T.,
Garcia,F., Haden,K., Li,J., Shaw,C.A., Belmont,J. et al. (2006)
High-resolution genomic proﬁling of chromosomal aberrations
using Inﬁnium whole-genome genotyping. Genome Res., 16,
1136–1148.
13. Sun,W., Wright,F.A., Tang,Z., Nordgard,S.H., Van Loo,P.,
Yu,T., Kristensen,V.N. and Perou,C.M. (2009) Integrated study
of copy number states and genotype calls using high-density SNP
arrays. Nucleic Acids Res., 37, 5365–5377.
14. Wang,K., Li,M., Hadley,D., Liu,R., Glessner,J., Grant,S.F.,
Hakonarson,H. and Bucan,M. (2007) PennCNV: an integrated
hidden Markov model designed for high-resolution copy number
variation detection in whole-genome SNP genotyping data.
Genome Res., 17, 1665–1674.
15. Staaf,J., Lindgren,D., Vallon-Christersson,J., Isaksson,A.,
Goransson,H., Juliusson,G., Rosenquist,R., Hoglund,M., Borg,A.
and Ringner,M. (2008) Segmentation-based detection of allelic
imbalance and loss-of-heterozygosity in cancer cells using whole
genome SNP arrays. Genome Biol., 9, R136.
16. Huang,J., Wei,W., Chen,J., Zhang,J., Liu,G., Di,X., Mei,R.,
Ishikawa,S., Aburatani,H., Jones,K.W. et al. (2006) CARAT: a
novel method for allelic detection of DNA copy number changes
using high density oligonucleotide arrays. BMC Bioinformatics,
7, 83.
17. Laframboise,T., Harrington,D. and Weir,B.A. (2007) PLASQ: a
generalized linear model-based procedure to determine allelic
dosage in cancer cells from SNP array data. Biostatistics, 8,
323–336.
18. Yamamoto,G., Nannya,Y., Kato,M., Sanada,M., Levine,R.L.,
Kawamata,N., Hangaishi,A., Kurokawa,M., Chiba,S.,
Gilliland,D.G. et al. (2007) Highly sensitive method for
genomewide detection of allelic composition in nonpaired,
primary tumor specimens by use of affymetrix
single-nucleotide-polymorphism genotyping microarrays.
Am. J. Hum. Genet., 81, 114–126.
19. Scharpf,R.B., Parmigiani,G., Pevsner,J. and Ruczinski,I. (2008)
Hidden Markov models for the assessment of chromosomal
alterations using high-throughput SNP arrays. Ann. Appl. Stat., 2,
687–713.
20. Korn,J.M., Kuruvilla,F.G., McCarroll,S.A., Wysoker,A.,
Nemesh,J., Cawley,S., Hubbell,E., Veitch,J., Collins,P.J.,
Darvishi,K. et al. (2008) Integrated genotype calling and
association analysis of SNPs, common copy number
polymorphisms and rare CNVs. Nat. Genet., 40, 1253–1260.
21. Colella,S., Yau,C., Taylor,J.M., Mirza,G., Butler,H., Clouston,P.,
Bassett,A.S., Seller,A., Holmes,C.C. and Ragoussis,J. (2007)
QuantiSNP: an Objective Bayes Hidden-Markov Model to detect
and accurately map copy number variation using SNP genotyping
data. Nucleic Acids Res., 35, 2013–2025.
22. Assie,G., LaFramboise,T., Platzer,P., Bertherat,J., Stratakis,C.A.
and Eng,C. (2008) SNP arrays in heterogeneous tissue: highly
accurate collection of both germline and somatic genetic
information from unpaired single tumor samples.
Am. J. Hum. Genet., 82, 903–915.
23. Nancarrow,D.J., Handoko,H.Y., Stark,M.S., Whiteman,D.C. and
Hayward,N.K. (2007) SiDCoN: a tool to aid scoring of DNA
copy number changes in SNP chip data. PLoS One, 2, e1093.
24. Attiyeh,E.F., Diskin,S.J., Attiyeh,M.A., Mosse,Y.P., Hou,C.,
Jackson,E.M., Kim,C., Glessner,J., Hakonarson,H., Biegel,J.A.
et al. (2009) Genomic copy number determination in cancer cells
from single nucleotide polymorphism microarrays based on
quantitative genotyping corrected for aneuploidy. Genome Res.,
19, 276–283.
25. Popova,T., Manie,E., Stoppa-Lyonnet,D., Rigaill,G., Barillot,E.
and Stern,M.H. (2009) Genome Alteration Print (GAP): a tool to
visualize and mine complex cancer genomic proﬁles obtained by
SNP arrays. Genome Biol., 10, R128.
26. Greenman,C.D., Bignell,G., Butler,A., Edkins,S., Hinton,J.,
Beare,D., Swamy,S., Santarius,T., Chen,L., Widaa,S. et al. (2010)
PICNIC: an algorithm to predict absolute allelic copy number
variation with microarray cancer data. Biostatistics, 11, 164–175.
27. Diskin,S.J., Li,M., Hou,C., Yang,S., Glessner,J., Hakonarson,H.,
Bucan,M., Maris,J.M. and Wang,K. (2008) Adjustment of
genomic waves in signal intensities from whole-genome SNP
genotyping platforms. Nucleic Acids Res., 36, e126.
28. Liu,Z., Li,A., Schulz,V., Chen,M. and Tuck,D. (2010) MixHMM:
inferring copy number variation and allelic imbalance using SNP
arrays and tumor samples mixed with stromal cells. PLoS ONE,
5, e10909.
29. Rabiner,L.R. (1989) A tutorial on hidden Markov models and
selected applications in speech recognition. Proc. IEEE, 77,
257–286.
30. Dempster,A.P., Laird,N.M. and Rubin,D.B. (1977) Maximum
likelihood from incomplete data via em algorithm. J. Roy. Stat.
Soc. B-Methodol., 39, 1–38.
31. RAO,S.S. (2009) Engineering Optimization: Theory and Practice.
Wiley-Interscience, New York, NY.
32. Staaf,J., Vallon-Christersson,J., Lindgren,D., Juliusson,G.,
Rosenquist,R., Hoglund,M., Borg,A. and Ringner,M. (2008)
Normalization of Illumina Inﬁnium whole-genome SNP data
improves copy number estimates and allelic intensity ratios.
BMC Bioinformatics, 9, 409.
33. Navin,N., Krasnitz,A., Rodgers,L., Cook,K., Meth,J., Kendall,J.,
Riggs,M., Eberling,Y., Troge,J., Grubor,V. et al. (2010) Inferring
tumor progression from genomic heterogeneity. Genome Res., 20,
68–80.
Nucleic Acids Research, 2011,Vol.39, No. 12 4941